Prasugrel

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009. It is grouped under the following drug class(es): Antiplatelets and Antithrombotic agents. Its therapeutic use is listed as cardiovascular and hematologic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Prasita and Efient. Its PubChem CID is 6918456.

CAS No 150322-43-3
Molecular Formula C20H20FNO3S
Molecular Weight 373.4 g/mol
Synonyms [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate

Frequently Asked Questions